[HTML][HTML] A guide to cancer immunotherapy: from T cell basic science to clinical practice
AD Waldman, JM Fritz, MJ Lenardo - Nature Reviews Immunology, 2020 - nature.com
The T lymphocyte, especially its capacity for antigen-directed cytotoxicity, has become a
central focus for engaging the immune system in the fight against cancer. Basic science …
central focus for engaging the immune system in the fight against cancer. Basic science …
Targeting immune checkpoints in hematological malignancies
Immune checkpoint blockade (ICB) therapies such as anti-programmed death 1 (PD-1) and
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …
PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma
The PDCD1-encoded immune checkpoint receptor PD-1 is a key tumor suppressor in T cells
that is recurrently inactivated in T cell non-Hodgkin lymphomas (T-NHLs). The highest …
that is recurrently inactivated in T cell non-Hodgkin lymphomas (T-NHLs). The highest …
Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study
This study aimed to assess the efficacy and safety of treatment with avelumab, an anti–
programmed death ligand 1 (PD-L1) antibody, in patients with relapsed or refractory …
programmed death ligand 1 (PD-L1) antibody, in patients with relapsed or refractory …
Updates on immunotherapy and immune landscape in renal clear cell carcinoma
Simple Summary Clear cell renal cell carcinomas (ccRCC) have several distinct
immunological features, including a high degree of immune infiltration and relatively low …
immunological features, including a high degree of immune infiltration and relatively low …
[HTML][HTML] Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression
NN Bennani, HJ Kim, LD Pederson… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Peripheral T-cell lymphomas (PTCL), a heterogeneous group of mature aggressive non-
Hodgkin's lymphomas, carry a worse prognosis for most subtypes when compared with their …
Hodgkin's lymphomas, carry a worse prognosis for most subtypes when compared with their …
Peripheral T cell lymphomas: from the bench to the clinic
D Fiore, LV Cappelli, A Broccoli, PL Zinzani… - Nature Reviews …, 2020 - nature.com
Peripheral T cell lymphomas (PTCLs) are a heterogeneous group of orphan neoplasms.
Despite the introduction of anthracycline-based chemotherapy protocols, with or without …
Despite the introduction of anthracycline-based chemotherapy protocols, with or without …
HTLV-1 bZIP factor: the key viral gene for pathogenesis
M Matsuoka, JM Mesnard - Retrovirology, 2020 - Springer
Human T cell leukemia virus type 1 (HTLV-1) causes adult T-cell leukemia-lymphoma (ATL)
and inflammatory diseases. The HTLV-1 bZIP factor (HBZ) gene is constantly expressed in …
and inflammatory diseases. The HTLV-1 bZIP factor (HBZ) gene is constantly expressed in …
PD-1 signalling defines and protects leukaemic stem cells from T cell receptor-induced cell death in T cell acute lymphoblastic leukaemia
X Xu, W Zhang, L Xuan, Y Yu, W Zheng, F Tao… - Nature cell …, 2023 - nature.com
T cell acute lymphoblastic leukaemia (T-ALL) is an aggressive malignancy with poor
prognosis, but a decisive marker and effective treatment for leukaemia stem cells (LSCs) …
prognosis, but a decisive marker and effective treatment for leukaemia stem cells (LSCs) …
CCR4 as a therapeutic target for cancer immunotherapy
O Yoshie - Cancers, 2021 - mdpi.com
Simple Summary CCR4 is a chemokine receptor selectively expressed on normal T cell
subsets such as type 2 helper T cells, skin-homing T cells and regulatory T cells, and on skin …
subsets such as type 2 helper T cells, skin-homing T cells and regulatory T cells, and on skin …